文献速递眼底病与葡萄膜炎

视网膜AAV基因治疗的免疫反应:对疗效与安全性的影响

Immune responses to retinal gene therapy using adeno-associated viral vectors - Implications for treatment success and safety.
PubMed 文献 · Prog Retin Eye Res · 2020-10-15

该综述评估视网膜基因治疗中AAV载体相关的免疫反应、毒性与炎症,指出AAV可激活先天模式识别受体及诱导衣壳特异性与转基因特异性T细胞反应和中和抗体,从而限制疗效;眼部的免疫豁免特性可能抑制这些反应,并讨论了调节免疫反应以提高安全性和疗效的策略。

要点

  • AAV可激活TLR-2和TLR-9等模式识别受体,释放炎症因子和I型干扰素。
  • AAV可诱导衣壳特异性及转基因特异性T细胞反应和中和性抗AAV抗体。
  • 临床试验中报告了眼内炎症和/或初始功能改善后疗效丧失,可能与抗病毒防御机制清除转导细胞有关。

核心结论

  • AAV载体相关的免疫反应可能解释视网膜基因治疗中观察到的眼内炎症和疗效丧失。
  • 眼部免疫豁免特性可能抑制AAV诱导的免疫反应,但调节免疫反应策略有望提高安全性和疗效。

研究设计与样本

  • 综述评估视网膜基因治疗研究中AAV相关免疫反应、毒性与炎症,并讨论调节策略。

主要发现

  • AAV激活TLR-2和TLR-9等模式识别受体,导致炎症细胞因子和I型干扰素释放。
  • AAV诱导衣壳特异性及转基因特异性T细胞反应和中和性抗AAV抗体,限制治疗效果。
  • 独立研究报告了眼内炎症和/或初始功能改善后疗效丧失,可能与靶向清除转导细胞有关。

关键数值与推荐

  • AAV介导的视网膜基因治疗中,voretigene neparvovec(Luxturna)获批用于治疗RPE65突变相关视网膜营养不良。

临床怎么用

  • 在视网膜AAV基因治疗中应监测眼内炎症和疗效丧失,并考虑免疫调节策略。

局限性

  • 综述未报告具体样本量、阈值或定量免疫反应数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Recombinant adeno-associated virus (AAV) is the leading vector for gene therapy in the retina. As non-pathogenic, non-integrating, replication deficient vector, the recombinant virus efficiently transduces all key retinal cell populations. Successful testing of AAV vectors in clinical trials of inherited retinal diseases led to the recent approval of voretigene neparvovec (Luxturna) for the treatment of RPE65 mutation-associated retinal dystrophies. However, studies applying AAV-mediated retinal gene therapy independently reported intraocular inflammation and/or loss of efficacy after initial functional improvements. Both observations might be explained by targeted removal of transduced cells via anti-viral defence mechanisms. AAV has been shown to activate innate pattern recognition receptors (PRRs) such as toll-like receptor (TLR)-2 and TLR-9 resulting in the release of inflammatory cytokines and type I interferons. The vector can also induce capsid-specific and transgene-specific T cell responses and neutralizing anti-AAV antibodies which both limit the therapeutic effect. However, the target organ of retinal gene therapy, the eye, is known as an immune-privileged site. It is characterized by suppression of inflammation and promotion of immune tolerance which might prevent AAV-induced immune responses. This review evaluates AAV-related immune responses, toxicity and inflammation in studies of retinal gene therapy, identifies influencing variables of these responses and discusses potential strategies to modulate immune reactions to AAV vectors to increase the safety and efficacy of ocular gene therapy.

来源:Prog Retin Eye Res,查看原文。版权归原作者所有。

引用

  1. Bucher K, Rodríguez-Bocanegra E, Dauletbekov D, et al. Immune responses to retinal gene therapy using adeno-associated viral vectors - Implications for treatment success and safety. Prog Retin Eye Res. 2020. PMID: 33069860. doi:10.1016/j.preteyeres.2020.100915

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。